Core Viewpoint - The Hong Kong Stock Connect Pharmaceutical ETF (513200) experienced a decline of 1.97% on November 7, with a trading volume of 191 million yuan, indicating a downward trend in the pharmaceutical sector [1] Group 1: Fund Performance - The ETF's total shares increased by 4 million, bringing the latest total to 1.813 billion shares, with a notable increase of 38 million shares over the past 20 trading days [1] - The latest net asset value of the ETF is calculated at 2.057 billion yuan [1] - Since its inception on January 19, 2022, the ETF has returned 13.45%, while its return over the past month has been -13.15% [1] Group 2: Management and Benchmark - The ETF is managed by E Fund Management Co., Ltd., with Wu Chendong as the fund manager [1] - The performance benchmark for the ETF is the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index return rate, adjusted using the valuation exchange rate [1]
11月7日港股通医药ETF（513200）份额增加400.00万份
Xin Lang Cai Jing·2025-11-10 04:19